Table 2 Meta-analyses of the correlation between LINC00511 expression and clinicopathological features
From: LINC00511 as a prognostic biomarker for human cancers: a systematic review and meta-analysis
Variables | Number of studies | Number of patients | Model | OR | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
95% CI | p-value | I2 (%) | PH | ||||
Gender (Male vs. Female) | 6 | 498 | Random | 0.98 (0.53–1.85) | 0.96 | 58 | 0.04 |
Age | |||||||
 ≥45 vs. < 45 | 1 | 84 | – | 0.66 (0.28–1.59) | 0.36 | – | – |
 ≥50 vs. < 50 | 6 | 462 | Fixed | 0.69 (0.47–1.01) | 0.06 | 0 | 0.98 |
 ≥60 vs. < 60 | 1 | 140 | – | 0.72 (0.34–1.52) | 0.39 | – | – |
 ≥65 vs. < 65 | 2 | 173 | Fixed | 0.59 (0.29–1.20) | 0.15 | 0 | 0.89 |
Histological grade (poor vs. well and moderate) | 8 | 725 | Fixed | 1.34 (0.97–1.85) | 0.07 | 0 | 0.75 |
Histological tumor type (adenocarcinoma vs. squamous cell carcinoma) | 3 | 300 | Random | 2.80 (0.58–13.59) | 0.20 | 71 | 0.03 |
Tumor size (large vs. small) | 11 | 916 | Random | 3.10 (1.97–4.86) | < 0.00001 | 50 | 0.03 |
Lymph node metastasis (positive vs. negative) | 10 | 880 | Fixed | 3.11 (2.30–4.21) | <  0.00001 | 42 | 0.08 |
Clinical stage (late vs. early) | 8 | 643 | Fixed | 3.95 (2.68–5.81) | < 0.00001 | 0 | 0.48 |
Distant metastasis (Yes vs. No) | 3 | 215 | Fixed | 2.39 (1.16–4.93) | 0.02 | 21 | 0.28 |
Recurrence (Yes vs. No) | 3 | 274 | Fixed | 4.62 (2.47–8.65) | < 0.00001 | 0 | 0.66 |